Long-term follow-up from the phase 1/2a GDFATHER-01 trial reported deep and durable remissions by combining the GDF-15-neutralizing antibody visugromab with nivolumab in patients with immunotherapy-resistant advanced solid tumors. The results position GDF-15 pathway blockade as a potential strategy to re-sensitize tumors that have already failed checkpoint-based therapy. The study’s emphasis on durability is notable: rather than relying on early tumor shrinkage alone, investigators report longer-lasting clinical responses consistent with meaningful immune re-engagement. This matters in resistant populations where options are often limited and durable benefit is difficult to achieve. The trial supports continued exploration of visugromab in combination regimens and may guide biomarker-focused efforts to identify which tumors are most likely to benefit from GDF-15 axis inhibition.